Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials

Reuters

02/02

<a href="https://laohu8.com/S/AORT">Artivion</a> Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials

Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial, which enrolled 94 high-risk patients with chronic aortic arch disease, reported 94% survival from lesion-related death and 91% freedom from disabling stroke at one year post-treatment. Additionally, 97% of patients were free from reintervention due to endoleaks, with no cases of renal failure and one instance of paraplegia observed. Data from the AMDS PERSEVERE IDE trial indicated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry (DANE) tears between one- and two-year follow-up. The results were presented at the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL75854) on February 02, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2608861843"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608861843\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608861843?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608861843","market":"nz","top_or_hot":-1,"title":"Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AORT\">Artivion</a> Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial, which enrolled 94 high-risk patients with chronic aortic arch disease, reported 94% survival from lesion-related death and 91% freedom from disabling stroke at one year post-treatment. Additionally, 97% of patients were free from reintervention due to endoleaks, with no cases of renal failure and one instance of paraplegia observed. Data from the AMDS PERSEVERE IDE trial indicated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry (DANE) tears between one- and two-year follow-up. The results were presented at the conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL75854) on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-02 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AORT\">Artivion</a> Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial, which enrolled 94 high-risk patients with chronic aortic arch disease, reported 94% survival from lesion-related death and 91% freedom from disabling stroke at one year post-treatment. Additionally, 97% of patients were free from reintervention due to endoleaks, with no cases of renal failure and one instance of paraplegia observed. Data from the AMDS PERSEVERE IDE trial indicated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry (DANE) tears between one- and two-year follow-up. The results were presented at the conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL75854) on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0031619046.USD","symbol_name":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL9bY3Sw:1","article_id":"2608861843","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608861843","pubTimestamp":1770037300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial, which enrolled 94 high-risk patients with chronic aortic arch disease, reported 94% survival from lesion-related death and 91% freedom from disabling stroke at one year post-treatment. Additionally, 97% of patients were free from reintervention due to endoleaks, with no cases of renal failure and one instance of paraplegia observed. Data from the AMDS PERSEVERE IDE trial indicated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry  tears between one- and two-year follow-up. The results were presented at the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","BK4082":"医疗保健设备","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","AORT":"Artivion","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC"},"translate_title":"Artivion在NEXUS TRIOMPHE和AMDS PERSEVERE试验中报告了高生存率和低发病率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AORT":0.9},"content_text":"Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials\n    \n\n        Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial, which enrolled 94 high-risk patients with chronic aortic arch disease, reported 94% survival from lesion-related death and 91% freedom from disabling stroke at one year post-treatment. Additionally, 97% of patients were free from reintervention due to endoleaks, with no cases of renal failure and one instance of paraplegia observed. Data from the AMDS PERSEVERE IDE trial indicated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry (DANE) tears between one- and two-year follow-up. The results were presented at the conference.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL75854) on February 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}